Stressed Out: RNA-binding Protein Inhabits Granules in ALS, FTD
Meet RBM45. This RNA-binding protein and relatively new player in the ALS field associates with stress-induced structures in the cytoplasm and nucleus.
588 RESULTS
Sort By:
Meet RBM45. This RNA-binding protein and relatively new player in the ALS field associates with stress-induced structures in the cytoplasm and nucleus.
NIH announced a five-year study of Alzheimer’s biomarkers in middle-aged people with Down’s syndrome.
Researchers will follow former football players at risk for the disorder to identify the best biomarkers and clinical criteria.
TREM2 levels tracked with tau, but varied widely among patients and carriers of different mutations, leaving it unclear whether TREM2 helps or hurts.
Study improves confidence in three core biomarkers and five emerging markers, most in cerebrospinal fluid and one in blood.
At a workshop of the Frontotemporal Dementia Treatment Study Group, advocates and regulatory scientists urged leaders from industry and academia to forge a collaborative approach while the field is still young.
Hoping for better luck in clinical trials than their Alzheimer’s colleagues had in the past decade, FTD researchers are now chasing biomarkers. It’s slim pickings so far, but neurofilament, tau PET, and MRI are showing promise.
Citing “fantastic opportunity,” FDA and EMA call for rigorous science. Agency scientists tell FTD Treatment Study Group: Explore individualized outcomes, and connect biomarkers to meaningful improvement.
Seeking strength in numbers, families gathered to swap stories and to learn about an upcoming DIAN-TU therapy trial geared specifically to their particular form of early onset AD.
A PET study comparing amyloid, tau, and volumetric imaging in preclinical AD identifies a region where local tangles correlate with brain-wide amyloid.
At AAIC, 28 scientific presentations and five attendant meetings of the Dominantly Inherited Alzheimer’s Network showed how data is rolling in while the platform expands to more countries and a second therapeutic trial.
Serial measurements on hundreds of people in the Dominantly Inherited Alzheimer’s Network put proposed staging diagrams on an empirical footing. CSF markers sTREM2 and VILIP-1 track tau.
At AAIC, updated imaging data in autosomal-dominant AD shows that longitudinal MRI in large numbers of people confirms atrophy patterns. Tau PET is more variable in DIAN participants than in the Colombian families.
Armed with what they consider comprehensive data sets from the DIAN initiative, researchers are beginning a quest to settle an old question that may become key to drug approvals for late-onset AD.
As data pours in, DIAN leaders strive to share and publish it without accidentally disclosing mutation status. The more is learned about preclinical AD, the harder this may get.